Mitomics said this week that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.

LabMD, an Atlanta-based clinical pathology laboratory, will distribute the test to its urology customers for patients with suspected prostate cancer who have a negative initial biopsy outcome.

PCMT is a PCR-based mitochondrial DNA test that detects the presence of cancerous cells using previously obtained prostate biopsy tissue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.